FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 485 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Blood test could tailor treatment after surgery July 14, 2021 Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ March 16, 2021 Surveillance and Early Cancer Detection are Associated with Improved Survival in... September 1, 2021 Program Connects Adolescents and Young Adults to Quality Cancer Care October 24, 2024 Load more HOT NEWS InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of... Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and...
